How validated receptor occupancy flow cytometry assays can impact decisions and support drug development.

about

How validated receptor occupancy flow cytometry assays can impact decisions and support drug development.

Item

http://www.wikidata.org/entity/Q38579129

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

How validated receptor occupan ...... and support drug development.

@en

type

Item

label

How validated receptor occupan ...... and support drug development.

@en

prefLabel

How validated receptor occupan ...... and support drug development.

@en

P1476

How validated receptor occupan ...... and support drug development.

@en

P2093

Marie-Laure Ozoux

http://www.w3.org/2001/XMLSchema#string

Maxime Moulard

http://www.w3.org/2001/XMLSchema#string

P2860

SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies

CD38 and CD157: a long journey from activation markers to multifunctional molecules

Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.

A phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma.

A humanized monoclonal antibody targeting the β7 integrin selectively blocks intestinal homing of T lymphocytes.

Comparison between internalizing anti-HER2 mAbs and non-internalizing anti-CEA mAbs in alpha-radioimmunotherapy of small volume peritoneal carcinomatosis using 212Pb.

MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.

P304

150-158

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CYTO.B.21320

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-08-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26332593

http://www.w3.org/2001/XMLSchema#string

How validated receptor occupancy flow cytometry assays can impact decisions and support drug development.

about

How validated receptor occupancy flow cytometry assays can impact decisions and support drug development.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698